In the meantime, this study reminds us that the doseresponse curve of incretin therapies is never just quantitative, but also qualitative: new doses can bring not only more efficacy, but also entirely new clinical scenarios in terms of safety
Members get access to personalized protocol builders, weight-based dosing calculators , and expert-reviewed reconstitution guides that account for individual factors most resources ignore
J Immunol 211(4):563575 Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V (2024) Asct2-targeting antibody-drug conjugate medi7247 in adult patients with relapsed/refractory hematological malignancies: a first-in-human, phase 1 study
Zhang, D